|   | |
| Clinical data | |
|---|---|
| Other names | N6-[(S)-1-(Phenyl)propyl]adenosine | 
| Drug class | Adenosine receptor agonist; Sedative; Hypnotic | 
| ATC code | 
 | 
| Identifiers | |
| 
 | |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C19H23N5O4 | 
| Molar mass | 385.424 g·mol−1 | 
| 3D model (JSmol) | |
| 
 | |
| 
 | |
YZG-331, also known as N6-[(S)-1-(phenyl)propyl]adenosine, is an adenosine receptor agonist which is or was under investigation for the potential treatment of insomnia. [1] [2] [3]
The drug appears to act through the adenosine A1 and A2A receptors. [3] It produces sedative and hypnotic effects and hypolocomotion in animals. [3] The drug is orally active and crosses the blood–brain barrier, although its intestinal absorption and central permeability may be reduced by its P-glycoprotein substrate activity. [4] [5] It is a synthetic derivative of adenosine and of N6-(4-hydroxybenzyl)adenine riboside (NHBA). [5] [3] The latter compound is found in the traditional Chinese medicinal herb Gastrodia elata . [5] [3]
YZG-331 was first described in the scientific literature by at least 2014. [6] As of 2025, it has reached the preclinical research stage of development. [1]
1. Adenosine Receptor Agonist. YZG-331 is a promising sedative hypnotic and adenosine analog that exerts its effects by binding to the adenosine receptor. (See the Other Receptors section for a review of the pharmacology of A1A and A2A.)